Menu

Parts of U.S. Saw an Increase in Zika-Linked Birth Defects in 2016

The rise occurred in areas with confirmed local transmission, according to a new CDC report. 

Jan 26, 2018
Katarina Zimmer

ISTOCK, NECKAEV-KON In the latter half of 2016, US jurisdictions with known local transmission of Zika saw a 21 percent increase in birth defects potentially linked to the virus, according to a report published today (January 26) by the Centers for Disease Control and Prevention (CDC).

“This finding underscores the importance of surveillance for birth defects potentially related to Zika virus infection and the need for continued monitoring in areas at risk for Zika transmission and exposure,” the authors write in the report.

The CDC team searched for cases of Zika-associated birth defects, such as microcephaly, in just under one million births that occured across 15 US states and territories in 2016. These included areas with documented cases of local Zika transmission (Puerto Rico, southern Florida, and a portion of southern Texas) and locations with confirmed instances of travel-associated Zika infections.

The researchers found that three of every 1,000 babies born in those areas had a birth defect that could have been linked to Zika infection in their mothers. When they specifically focused on areas with local transmission and excluded birth defects with weaker links to Zika, such as neural tube defects and other early brain malformations, they found a statistically significant increase in the number of Zika-linked birth defects in the second half of 2016 compared to the first.  

The study authors expect another potential increase of Zika-related birth defects in 2017, given that the peak of confirmed local transmission occurred in the second half of 2016.

Brenda Fitzgerald, director of the CDC, and her colleagues argue that these numbers might only represent a fraction of the full effect of congenital Zika virus infections. “[S]ome healthy infants born following pregnancies complicated by Zika may have developmental problems that become evident later,” they write in a JAMA commentary. “[O]ngoing surveillance is needed to determine the extent to which congenitally exposed infants without apparent birth defects will experience similar or other developmental issues.”

The number of laboratory-confirmed Zika cases has declined since 2016, according to CDC data. Some scientists believe that this is because much of the population in the Americas developed immunity to the virus, Science reported last year.

Nevertheless, there are ongoing efforts to develop Zika vaccines to prevent future epidemics and to control populations of Zika-carrying mosquito species. 

See “Zika Vaccine Shows Promise in Early Clinical Trial

CENTERS FOR DISEASE CONTROL AND PREVENTION

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.